Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan

被引:15
作者
Dahlof, CGH
Falk, L
Risenfors, M
Lewis, CP
机构
[1] Sociala Huset, Gothenburg Migraine Clin, S-41117 Gothenburg, Sweden
[2] Cent Hosp Molndal, SU, Dept Cardiol, Molndal, Sweden
[3] Bristol Myers Squibb Pharmaceut Res Inst, Wallingford, CT USA
关键词
adverse events; avitriptan; chest symptoms; migraine; safety;
D O I
10.1046/j.1468-2982.1998.1808546.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We investigate whether symptoms of pressure, tightness, and/or pain in the chest, neck, and/or throat after administration of the 5HT(1B/1D) agonist avitriptan were associated with objective impairment of the myocardial function on 12-lead electrocardiogram (ECC), continuous ECG (Wolter) monitoring, and echocardiography. Migraine sufferers who in two-thirds of all attacks treated with sumatriptan had experienced chest/throat/neck symptoms were chosen for study. Baseline measures included vital signs, a 12-lead ECG and an echocardiogram. Patients (n=51) who had no clinically significant abnormality at baseline received a high dose (150 mg) of avitriptan orally outside of a migraine attack. If pressure, tightness, and/or pain. in the chest, neck, and/or throat occurred, an ECG was obtained, and a repeat echocardiogram was done while the symptoms were present in order to monitor for impairment of myocardial function. If symptoms of these types did not occur within 60 min after administration of the study drug, a second echocardiogram was obtained. Forty-five patients (88%) reported at least one adverse event and 23 (45%) experienced pressure, tightness, and/or pain in the chest, neck, and/or throat after administration of avitriptan. No clinically significant myocardial abnormalities were observed in any patient, even in those who had experienced the targeted symptoms. No other serious adverse event occurred. We concluded that the typical 5HT(1B/1D) agonist-induced chest/throat/neck symptoms are most unlikely to be of cardiovascular origin.
引用
收藏
页码:546 / 551
页数:6
相关论文
共 57 条
[11]  
Dahlof CGH, 1995, CEPHALALGIA, V15, P21
[12]  
de Jong E G, 1992, Ned Tijdschr Geneeskd, V136, P2142
[13]   SUMATRIPTAN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN THE ACUTE TREATMENT OF MIGRAINE AND CLUSTER HEADACHE [J].
DECHANT, KL ;
CLISSOLD, SP .
DRUGS, 1992, 43 (05) :776-798
[14]   Migraine [J].
Ferrari, MD .
LANCET, 1998, 351 (9108) :1043-1051
[15]   Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)(1B/D) receptor agonist zolmitriptan (311C90): Are brain stem sites therapeutic target in migraine? [J].
Goadsby, PJ ;
Hoskin, KL .
PAIN, 1996, 67 (2-3) :355-359
[16]  
GOADSBY PJ, 1995, EXPT HEADACHE MODELS
[17]   Sumatriptan nasal spray (20 mg/dose) in the acute treatment of cluster headache [J].
Hardebo, JE ;
Dahlof, C .
CEPHALALGIA, 1998, 18 (07) :487-489
[18]   Alignment of receptor nomenclature with the human genome: Classification of 5-HT1B and 5-HT1D receptor subtypes [J].
Hartig, PR ;
Hoyer, D ;
Humphrey, PPA ;
Martin, GR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (03) :103-105
[19]  
HILLIS WS, 1993, LANCET, V342, P683
[20]   SUMATRIPTAN-INDUCED CHEST PAIN [J].
HOOD, S ;
BIRNIE, D ;
MACINTYRE, PD ;
HILLIS, WS .
LANCET, 1994, 344 (8935) :1500-1501